新型抗疱疹药物的药理学：泛昔洛韦和伐昔洛韦。

Pharmacology of new antiherpes agents: famciclovir and valacyclovir.

作者信息

Stein G E

机构信息

Department of Medicine, Michigan State University, Lansing, USA.

出版信息

J Am Pharm Assoc (Wash). 1997 Mar-Apr;NS37(2):157-63. doi: 10.1016/s1086-5802(16)30202-9.

DOI:10.1016/s1086-5802(16)30202-9

PMID:9069689

Abstract

Limitations of acyclovir in treating infections caused by herpes simplex virus include the development of resistant isolates and relatively poor oral bioavailability. Penciclovir and famciclovir may have added clinical utility in the treatment of herpes virus infections in humans. Intracellular pharmacokinetics differ for valacyclovir and famciclovir, but the importance of these differences is unknown. Animal studies suggest that famciclovir (but not valacyclovir) can affect subsequent latent infection with HSV-1; the relevance of these findings to humans requires further investigation. Famciclovir and valacyclovir appear to decrease time to resolution of pain compared with acyclovir in patients with herpes zoster infections.

摘要

阿昔洛韦在治疗单纯疱疹病毒引起的感染方面存在局限性，包括耐药菌株的出现以及相对较差的口服生物利用度。喷昔洛韦和泛昔洛韦在治疗人类疱疹病毒感染方面可能具有额外的临床效用。伐昔洛韦和泛昔洛韦的细胞内药代动力学有所不同，但这些差异的重要性尚不清楚。动物研究表明，泛昔洛韦（而非伐昔洛韦）可影响随后的HSV-1潜伏感染；这些发现与人类的相关性需要进一步研究。与阿昔洛韦相比，泛昔洛韦和伐昔洛韦似乎可缩短带状疱疹感染患者疼痛缓解的时间。